Results 41 to 50 of about 118,941 (325)

Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes [PDF]

, 2020
Background Both Alzheimer's disease (AD) and type 2 diabetes (T2D) share common pathological features including inflammation, insulin signaling alterations, or vascular damage.
Alves-Martinez, Pilar, Carranza-Naval, María José, García Alloza, Mónica, Herrera, Marta, Hierro Bujalance, Carmen, Infante-Garcia, Carmen, Lubián López, Simón Pedro, Marco González, Ángel José del, Suarez, Javier   +8 more
core   +1 more source

Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology

European Journal of Heart Failure, 2020
Heart failure (HF) is common and associated with a poor prognosis, despite advances in treatment. Over the last decade cardiovascular outcome trials with sodium–glucose co‐transporter 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus have ...
P. Seferovic, G. Fragasso, M. Petrie, W. Mullens, R. Ferrari, T. Thum, J. Bauersachs, S. Anker, R. Ray, Y. Cavusoglu, M. Polovina, M. Metra, G. Ambrosio, K. Prasad, J. Seferovic, P. Jhund, G. Dattilo, J. Čelutkienė, M. Piepoli, B. Moura, O. Chioncel, T. Ben Gal, S. Heymans, R. A. Boer, T. Jaarsma, L. Hill, Y. Lopatin, A. Lyon, P. Ponikowski, M. Lainščak, E. Jankowska, C. Mueller, F. Cosentino, L. Lund, G. Filippatos, F. Ruschitzka, A. Coats, G. Rosano   +37 more
semanticscholar   +1 more source

New Diabetes Therapies and Diabetic Kidney Disease Progression:the Role of SGLT-2 Inhibitors [PDF]

, 2018
Purpose of Review Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have emerged as a promising drug class for the treatment of diabetic kidney disease.
Dekkers, Claire C. J., Gansevoort, Ron T., Heerspink, Hiddo J. L.   +2 more
core   +2 more sources

Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review.

Journal of the American College of Cardiology, 2018
Patients with type 2 diabetes mellitus have an increased risk for the development of cardiac and other vascular events, heart failure (HF), and decline in renal function.
Thomas A. Zelniker, E. Braunwald
semanticscholar   +1 more source

Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of anti-diabetic agents

Drugs in Context, 2014
Although several treatment options are available to reduce hyperglycemia, only about half of individuals with diagnosed diabetes mellitus (DM) achieve recommended glycemic targets.
Eva M Vivian
doaj   +1 more source

Fournier's gangrene and sodium-glucose co-transporter 2(SGLT2) inhibitors: Our experience

Indian Journal of Endocrinology and Metabolism, 2019
Ashwitha S Dass, Gloria Immaculate, Arpandev Bhattacharyya   +2 more
doaj   +3 more sources

Sodium-glucose co-transporter-2 inhibitors in heart failure and chronic kidney disease: the role of empagliflozin

Российский кардиологический журнал, 2021
The development of chronic kidney disease (CKD) is a risk factor not only for cardiovascular diseases, but also for heart failure (HF). This article is a literary review on the use of Sodium-glucose co-transporter-2 (NGLT2) inhibitors in patients with ...
M. M. Batyushin
doaj   +1 more source

Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes [PDF]

, 2012
Background Despite the number of medications for type 2 diabetes, many people with the condition do not achieve good glycaemic control. Some existing glucose-lowering agents have adverse effects such as weight gain or hypoglycaemia. Type 2 diabetes tends
Clar, C., Court, Rachel A., Gill, J. A. (James Alexander), Waugh, Norman   +3 more
core   +1 more source

Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review.

British Journal of Anaesthesia, 2019
BACKGROUND Perioperative diabetic ketoacidosis (DKA) with near-normal blood glucose concentrations, termed euglycaemic ketoacidosis (EDKA), is an adverse effect associated with sodium-glucose co-transporter-2 inhibitors (SGLT2i).
V. Thiruvenkatarajan, E. Meyer, N. Nanjappa, R. van Wijk, D. Jesudason   +4 more
semanticscholar   +1 more source

All‐cause mortality and cardiovascular outcomes with sodium‐glucose Co‐transporter 2 inhibitors, glucagon‐like peptide‐1 receptor agonists and with combination therapy in people with type 2 diabetes

Diabetes, obesity and metabolism, 2023
To assess the relationship of sodium‐glucose cotransporter‐2 inhibitors (SGLT2i), glucagon‐like peptide‐1 receptor analogues (GLP‐1RA) and their combination (SGLT2i + GLP‐1RA) with 5‐year risk of all‐cause mortality, hospitalization and cardiovascular ...
David R. Riley, H. Essa, P. Austin, Frank G. Preston, Isatu Kargbo, G. H. Ibarburu, Ramandeep Ghuman, D. Cuthbertson, G. Lip, U. Alam   +9 more
semanticscholar   +1 more source